PYC Therapeutics Ltd
ASX:PYC
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.7511
2.05
|
Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one PYC stock under the Base Case scenario is 1.19 AUD. Compared to the current market price of 1.9 AUD, PYC Therapeutics Ltd is Overvalued by 37%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
PYC Therapeutics Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for PYC cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
PYC Therapeutics Ltd
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
PYC Therapeutics Ltd
Balance Sheet Decomposition
PYC Therapeutics Ltd
Current Assets | 85.6m |
Cash & Short-Term Investments | 66.9m |
Receivables | 18m |
Other Current Assets | 744k |
Non-Current Assets | 5.6m |
PP&E | 1.6m |
Intangibles | 4.1m |
Current Liabilities | 9.1m |
Accounts Payable | 7.5m |
Accrued Liabilities | 1.3m |
Other Current Liabilities | 316.1k |
Non-Current Liabilities | 1.6m |
Long-Term Debt | 803k |
Other Non-Current Liabilities | 833.1k |
Earnings Waterfall
PYC Therapeutics Ltd
Revenue
|
22.9m
AUD
|
Operating Expenses
|
-60.4m
AUD
|
Operating Income
|
-37.6m
AUD
|
Other Expenses
|
-158k
AUD
|
Net Income
|
-37.7m
AUD
|
Free Cash Flow Analysis
PYC Therapeutics Ltd
AUD | |
Free Cash Flow | AUD |
PYC Therapeutics has made a strong start to 2024, focusing on advancing three first-in-class drugs targeting genetic diseases. The company aims to establish human safety and efficacy profiles for these drugs by the end of 2025, setting the stage for new drug applications by 2028. Recent data revealed promising safety and preliminary efficacy in their RP11 program. PYC is excited about the potential of these drugs to move through late-stage development successfully, with plans for commercial launch in 2028. The company's strategic focus and encouraging early results signal a significant step towards becoming a commercial-stage company.
What is Earnings Call?
PYC Profitability Score
Profitability Due Diligence
PYC Therapeutics Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
PYC Therapeutics Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
PYC Solvency Score
Solvency Due Diligence
PYC Therapeutics Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
PYC Therapeutics Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PYC Price Targets Summary
PYC Therapeutics Ltd
According to Wall Street analysts, the average 1-year price target for PYC is 3.37 AUD with a low forecast of 2.42 AUD and a high forecast of 4.62 AUD.
Dividends
Current shareholder yield for PYC is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
PYC Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
PYC Therapeutics Ltd. is a drug-development company, which offers a new generation of RNA therapeutics to meet unmet need in disease. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2005-03-30. The firm has RNA targeted therapeutics design capabilities to deliver technology based on cell penetrating peptides (CPPs). The firm develops a pipeline of therapies, including three preclinical stage programs, which are focused on inherited eye diseases and preclinical discovery efforts, which are focused on neurodegenerative diseases. The Company’s lead drug candidate, VP-001 is designed to treat Retinitis pigmentosa 11 (RP11). The second lead drug candidate VP-002, which is focused on treating autosomal dominant optic atrophy (ADOA) and PYC-001 drug candidate to treat diabetic retinopathy. Its preclinical, clinical, regulatory and corporate operations are based in San Diego, California. The firm's discovery and laboratory operations are located in Australia.
Contact
IPO
Employees
Officers
The intrinsic value of one PYC stock under the Base Case scenario is 1.19 AUD.
Compared to the current market price of 1.9 AUD, PYC Therapeutics Ltd is Overvalued by 37%.